Coronavirus Drug Discovery

Coronavirus Drug Discovery

Volume 3: Druggable Targets and In Silico Update

1st Edition - July 1, 2022

Write a review

  • Editor: Chukwuebuka Egbuna
  • Paperback ISBN: 9780323955782

Purchase options

Purchase options
Available for Pre-Order
Sales tax will be calculated at check-out

Institutional Subscription

Support CenterReturns & Refunds
Free Global Shipping
No minimum order

Description

Coronavirus Drug Discovery, Volume Three: Druggable Targets and In Silico Update presents comprehensive information on drug discovery against COVID-19. Chapters in Part One of this volume describe the various druggable targets and associated signaling pathways for effective targeting of SARS-CoV-2. In Part Two, chapters discuss the various computational approaches and in silico studies against SARS-CoV-2. Written by global team of experts, this book is an excellent resource that will be extremely useful to drug developers, medicinal chemists, pharmaceutical companies in R&D, research institutes in both academia and industry, and the National Library of Medicines and Health. In addition, agencies such as the National Institutes of Health, Centers for Disease Control and Prevention, World Health Organization, European Medicines Agency, the US Food and Drug Administration, and all others involved in drug discovery against COVID-19 will find this book useful.

Key Features

  • Discusses the pathogenic mechanisms of SARS-CoV-2 and druggable targets
  • Reviews the various signaling pathways associated with SAR-CoV-2 as possible druggable targets
  • Presents computational approaches and in silico studies against SARS-CoV-2

Readership

Researchers in organic and medicinal chemistry including drug developers and medicinal chemists, virologists, toxicologists, analytical chemists. Researchers in pharmaceutical and biotech industries

Table of Contents

  • PART 1: DRUGGABLE TARGETS AND SIGNALING PATHWAYS 
    1. SARS-CoV-2 genome sequencing and promising druggable targets
    2. Signaling pathways implicated in SARS-CoV2 infection
    3. Roles of membrane lipids and lipid synthesis inhibitors in the propagation of coronavirus disease
    4. Potential Drugs in SARS-CoV-2 Treatment: Key Features and Mechanisms of Actions

    PART 2: COMPUTATIONAL APPROACHES
    5. Application of computational tools for coronavirus drug discovery
    6. In silico Approaches in Drug Discovery for SARS-CoV-2
    7. Application of molecular docking and dynamics tools in SARS-CoV-2 drug design: Ligand-protein interaction studies
    8. Molecular dynamic simulation with protein and detection of repurposable drugs for COVID-19 
    9. Computation-guided inhibitor screening against the nucelocapsid of SARS-CoV-2 
    10. In-silico insight into the interaction of 4-aminoquinolines with selected SARS-CoV-2 structural and non-structural proteins 
    11. In silico Evaluation of Anti-SARS-CoV-2 Activity of Punica granatum L. Phytochemicals
    12. In silico Investigation and Identification of Bioactive Compounds from Medicinal Plants as Potential Inhibitors against SARS-CoV-2 Cellular Entry 

Product details

  • No. of pages: 418
  • Language: English
  • Copyright: © Elsevier 2022
  • Published: July 1, 2022
  • Imprint: Elsevier
  • Paperback ISBN: 9780323955782

About the Editor

Chukwuebuka Egbuna

Chukwuebuka Egbuna is a chartered chemist, a chemical analyst, and an academic researcher. He is a member of the Institute of Chartered Chemists of Nigeria (ICCON), the Nigerian Society of Biochemistry and Molecular Biology (NSBMB), the Society of Quality Assurance (SQA) (USA), and the Royal Society of Chemistry (RSC) (United Kingdom). Egbuna is also an editor of new Elsevier series on Drug Discovery Update. The series includes books, monographs and edited collections from all areas of drug discovery, including emerging therapeutic claims for the treatment of diseases. He has been engaged in a number of roles at New Divine Favor Pharmaceutical Industry Limited, Akuzor Nkpor, Anambra State, Nigeria, and Chukwuemeka Odumegwu Ojukwu University (COOU) in Nigeria. He has collaboratively worked and published quite a number of research articles in the area of phytochemistry, nutrition and toxicology and related areas. He is a reviewer and editorial board member of various journals, including serving as a website administrator for the Tropical Journal of Applied Natural Sciences (TJANS), a journal of the faculty of Natural Sciences, COOU and as an advisory board member under toxicology for the book publisher, Cambridge Scholar Publishing. His primary research interests are in phytochemistry, nutrition and toxicology, food and medicinal chemistry, and analytical biochemistry.

Affiliations and Expertise

Nutritional Biochemistry Unit, Africa Centre of Excellence in Public Health and Toxicological Research (ACE-PUTOR), University of Port-Harcourt, Rivers State; Department of Biochemistry, Chukwuemeka Odumegwu Ojukwu University, Uli, Nigeria

Ratings and Reviews

Write a review

There are currently no reviews for "Coronavirus Drug Discovery"